GET DAILY SIGNALSUroGen Pharma (URGN) Reports Strong Revenue Growth and Narrowed Losses in Q3
Key Takeaways
- Total revenue reached $89.0 million, up sharply from $27.5 million a year earlier, though it came in slightly below consensus estimates of about $90.6 million.
- The net loss narrowed dramatically to $1.5 million, or $0.03 per share, versus $33.3 million, or $0.69 per share, in the prior-year quarter, beating consensus EPS expectations.
- Zesturi generated $68.0 million in net product revenue, a 35% sequential increase driven by broader prescriber adoption and growing repeat utilization.
- Jelmyto posted $21 million in revenue, and management updated full-year Jelmyto guidance to approximately $90 million.
- The FDA accepted UroGen's New Drug Application (NDA) for UGN-103 and assigned a PDUFA goal date of June 14, 2027.
- Cash, cash equivalents, and marketable securities totaled $90.5 million at quarter end.
Earnings Context and Why It Matters
UroGen Pharma's third-quarter report marks an important checkpoint as the company moves from clinical-stage development toward a more scaled commercial operation. The results show whether URGN’s flagship Zesturi treatment for low-grade, intermediate-risk non-muscle invasive bladder cancer can maintain the momentum seen in the second quarter. Revenue more than tripled year over year while the net loss narrowed sharply, giving investors a clearer view of the path toward profitability. The quarter also brought notable pipeline progress with FDA acceptance of the UGN-103 application.
Reported Results
UroGen Pharma reported total revenue of $89.0 million for the third quarter ended September 30, 2026, compared with $27.5 million in the same period a year ago. The figure came in just below consensus estimates near $90.6 million. Net loss improved to $1.5 million, or $0.03 per share, from a net loss of $33.3 million, or $0.69 per share, in the third quarter of 2025 — and ahead of the consensus EPS estimate of a $0.05 loss. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Product performance drove the top line. Zesturi contributed $68.0 million in net product revenue, up 35% quarter over quarter. Jelmyto, used to treat low-grade upper tract urothelial cancer, generated $21 million, down from $22 million in the second quarter partly due to a one-time gross-to-net adjustment. Research and development expenses rose to $26.0 million from $14.0 million a year earlier, reflecting continued investment in UGN-103 and other programs.
Market Reaction and Investor Sentiment
Despite a solid bottom-line beat and robust Zesturi growth, URGN shares declined roughly 10% after the release. The reaction appeared tied to the modest revenue miss and a cautious near-term outlook. Management reiterated expectations for quarter-over-quarter Zesturi growth while noting typical holiday seasonality in the fourth quarter. Sentiment also reflected the impact of competing clinical trials on Jelmyto patient starts. The stock’s response highlights how closely it is now linked to launch execution and adoption trends among urology practices.
Forward Outlook and Key Factors to Monitor
Several catalysts stand out in the coming quarters. The most critical remains the continued scaling of Zesturi. Management highlighted encouraging adoption metrics, with unique prescribers rising to 662 from 452 in the prior quarter and repeat prescribers now accounting for about 50% of total writers. Maintaining this pace will be key to reaching the profitability target supported by existing cash resources.
Regulatory milestones also matter. The FDA’s acceptance of the UGN-103 NDA, with a PDUFA goal date of June 14, 2027, positions the company for a potential franchise extension. UroGen plans to pursue a permanent reimbursement J-code, with a full commercial launch targeted for 2028. Beyond UGN-103, enrollment in the UGN-104 Phase 3 trial is expected to finish by late 2026 or early 2027, while UGN-501 has begun dosing with initial data anticipated in 2027. Rising R&D and SG&A spending will warrant attention if revenue growth slows. From what I see, the balance between Zesturi’s commercial momentum and pipeline investment defines the near-term story for URGN.
Exploring AI-Powered Research Tools
In my own analysis, I frequently use Tickeron’s AI Screener to filter biotech opportunities and compare performance metrics across similar names. It streamlines the process of identifying relevant signals and helps put quarterly results like these into broader context without manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for URGN turns negative, indicating new downward trend
URGN saw its Momentum Indicator move below the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 70 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where URGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for URGN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where URGN's RSI Oscillator exited the oversold zone, 24 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 67 cases where URGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for URGN just turned positive on November 02, 2026. Looking at past instances where URGN's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.
Following a +5.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where URGN advanced for three days, in 213 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
URGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-12.700) is normal, around the industry mean (3.051). P/E Ratio (-17.462) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (11.403) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. URGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapies for urological pathologies
Industry Biotechnology
Advertisement